Featured White Papers
- Oct. 14th: Simplified IT with Software-as-a-Service (SaaS) (ZDNet)
- PCI DSS therapy for the smaller retailer (McAfee)
- The rise of Web commuting (Citrix Online)
Content provided in partnership with
Health Care Industry
Industry: Email Alert RSS FeedZinecard approval
OB/GYN News, Feb 1, 2003
Zinecard (dexrazoxane for injection) is now indicated for reducing the incidence and severity of cardiomyopathy that is associated with doxorubicin administration in those women with metastatic breast cancer, who have received a cumulative doxorubicin dose of 300 mg / [m.sup.2] and who will continue to receive doxorubicin to maintain tumor control.
However, the drug is not recommended for use with the initiation of doxorubicin therapy in patients. For more information, contact Pharmacia Corporation, 800-323-4202, www.pharmacia.com.
COPYRIGHT 2003 International Medical News Group
COPYRIGHT 2008 Gale, Cengage Learning
Find Research Guides for:
Find Featured Titles for: Business
- Academy of Marketing Science Review
- Accounting Historians Journal, The
- Accounting History
- AgExporter
- Agricultural Research
- Agricultural and Resource Economics Review
- Air Force Comptroller
- Air Safety Week
- Airline Industry Information
- American Demographics
- American Journal of Potato Research
- Architectural Review, The
- Asian Economic News
- Entrepreneur
Most Popular Articles in Health
- Fuel your workout: exercisers who eat before they work out have more energy ...
- Soothe a dry, itchy scalp: 5 easy expert solutions
- Cocktails and calories: Beer, wine and liquor calories can really add up. ...
- The sour truth about apple cider vinegar - evaluation of therapeutic use
- The, six best supplements you've never heard of: these secret weapons can ...
- More »